Update Will Change Buprenorphine MME Display in Most State PMPs
The
AMA and American Society of Addiction Medicine (ASAM) worked with Appriss
Health, the developer of more than 40 state PDMP platforms, to ensure that
buprenorphine for the treatment of opioid-use disorder has been removed from
all displayed morphine milligram equivalent (MME) calculations throughout its
system.
Appriss
Health reported that it deployed a full system update on April 11, 2018, that
clearly separates buprenorphine from opioids that are used for the treatment of
chronic pain. The company also strengthened guidance to exclude medications
used for medication-assisted treatment from Centers for for Disease Control and
Prevent-recommended MME limits (i.e. 90 MME per day).
|